Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis

The majority of disease modifying therapies for multiple sclerosis (MS) reduce inflammation, but do no’t target remyelination. Development of remyelinating therapies will benefit from a method to quantify myelin kinetics in patients with MS. We labeled myelin in vivo with deuterium, and modeled kine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanhai, Kawita M. S., Goulooze, Sebastiaan C., van der Grond, Jeroen, Harms, Amy C., Hankemeier, Thomas, Verma, Ajay, Dent, Gersham, Chavez, Juan, Meijering, Henri, Groeneveld, Geert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932820/
https://www.ncbi.nlm.nih.gov/pubmed/34799987
http://dx.doi.org/10.1111/cts.13181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932820/
https://www.ncbi.nlm.nih.gov/pubmed/34799987
http://dx.doi.org/10.1111/cts.13181

Ejemplares similares